Suven Life Sciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹67.49
- Today's High:
- ₹74.19
- Open Price:
- ₹74.19
- 52W Low:
- ₹45.01
- 52W High:
- ₹78.187
- Prev. Close:
- ₹69.8
- Volume:
- 223727
Company Statistics
- Market Cap.:
- ₹14.57 billion
- Book Value:
- 17.211
- Revenue TTM:
- ₹138.53 million
- Operating Margin TTM:
- -1002.93%
- Gross Profit TTM:
- ₹135.39 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -33.18%
- Return on Equity TTM:
- -50.17%
Company Profile
Suven Life Sciences Limited had its IPO on under the ticker symbol SUVEN.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Suven Life Sciences Limited has a staff strength of 132 employees.
Stock update
Shares of Suven Life Sciences Limited opened at ₹74.19 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹67.49 - ₹74.19, and closed at ₹72.55.
This is a +3.94% increase from the previous day's closing price.
A total volume of 223,727 shares were traded at the close of the day’s session.
In the last one week, shares of Suven Life Sciences Limited have increased by +10.58%.
Suven Life Sciences Limited's Key Ratios
Suven Life Sciences Limited has a market cap of ₹14.57 billion, indicating a price to book ratio of 24.2315 and a price to sales ratio of 56.0311.
In the last 12-months Suven Life Sciences Limited’s revenue was ₹138.53 million with a gross profit of ₹135.39 million and an EBITDA of ₹-1325691520. The EBITDA ratio measures Suven Life Sciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Suven Life Sciences Limited’s operating margin was -1002.93% while its return on assets stood at -33.18% with a return of equity of -50.17%.
In Q2, Suven Life Sciences Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7.3%.
Suven Life Sciences Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-6.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Suven Life Sciences Limited’s profitability.
Suven Life Sciences Limited stock is trading at a EV to sales ratio of 81.9189 and a EV to EBITDA ratio of -15.4218. Its price to sales ratio in the trailing 12-months stood at 56.0311.
Suven Life Sciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹3.89 billion
- Total Liabilities
- ₹111.30 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Suven Life Sciences Limited ended 2024 with ₹3.89 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹3.89 billion while shareholder equity stood at ₹3.75 billion.
Suven Life Sciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹111.30 million in other current liabilities, 218074000.00 in common stock, ₹3.54 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹370.19 million and cash and short-term investments were ₹2.31 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.00.
Suven Life Sciences Limited’s total current assets stands at ₹2.52 billion while long-term investments were ₹0 and short-term investments were ₹463.39 million. Its net receivables were ₹8.07 million compared to accounts payable of ₹16.65 million and inventory worth ₹0.00.
In 2024, Suven Life Sciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Suven Life Sciences Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹72.55
- 52-Week High
- ₹78.187
- 52-Week Low
- ₹45.01
- Analyst Target Price
- ₹
Suven Life Sciences Limited stock is currently trading at ₹72.55 per share. It touched a 52-week high of ₹78.187 and a 52-week low of ₹78.187. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹64.56 and 200-day moving average was ₹60.7 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7206.5% of the company’s stock are held by insiders while 253.6% are held by institutions.
Frequently Asked Questions About Suven Life Sciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.